Demars Financial Group LLC Lowers Stock Position in Eli Lilly and Company $LLY

Key Points

• Demars Financial Group LLC drastically reduced its holdings in Eli Lilly and Company by 99.9%, leaving it with only 757 shares after selling 618,761 shares.
• Several institutional investors, including Precedent Wealth Partners LLC and Capital Advisors Inc. OK, have increased their holdings in Eli Lilly, underscoring a shift in investor sentiment.
• Despite these changes in ownership, analysts remain optimistic with a consensus rating of "Moderate Buy" and a price target of $939.12 for Eli Lilly shares.

Demars Financial Group LLC lowered its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 99.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 757 shares of the company's stock after selling 618,761 shares during the period. Demars Financial Group LLC's holdings in Eli Lilly and Company were worth $590,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Precedent Wealth Partners LLC increased its holdings in Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock worth $229,000 after buying an additional 39 shares during the last quarter. Capital Advisors Inc. OK increased its holdings in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock worth $5,260,000 after buying an additional 429 shares during the last quarter. Family CFO Inc purchased a new stake in Eli Lilly and Company during the second quarter worth about $54,000. Duquesne Family Office LLC raised its position in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after purchasing an additional 32,640 shares during the period. Finally, Corient IA LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter valued at approximately $570,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on LLY shares. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Cantor Fitzgerald set a $925.00 price target on shares of Eli Lilly and Company and gave the company an "overweight" rating in a research note on Thursday, October 9th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Finally, DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $939.12.

Eli Lilly and Company Trading Down 1.9%

Shares of Eli Lilly and Company stock opened at $803.53 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The firm has a market cap of $760.51 billion, a PE ratio of 52.52, a PEG ratio of 1.15 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a 50 day simple moving average of $753.09 and a two-hundred day simple moving average of $765.70.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the business posted $3.92 earnings per share. Eli Lilly and Company's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock valued at $2,894,841 over the last quarter. Company insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.